A defined product and indication
Check the current authorisation, patient group and treatment setting. Approval for one use does not authorise every use of the same cell type.
Transparency
Evidence and sources
The public source categories used to research clinical status, patient safety and treatment pathways. Direct institutional confirmation is still required for current international access.
Regulatory status and patient access are separate
A study with eligibility rules
Check the protocol, registry, ethics review and study team. Registration and study participation do not establish a marketed treatment or guarantee benefit.
A proposal requiring verification
A price, hospital news report or “available” label is not proof of regulatory authorisation. Obtain the exact legal route and an individual written plan before payment.
RMC records the source, date, product or technique, proposed use and limits of each claim. Hospital expertise, research registration and a sales quotation answer different questions. None alone establishes access for an international patient.
Editorial source check: . This is a check of published information, not clinician review or direct confirmation from an institution.
China: the applicable legal route
The biomedical new-technology regulation took effect on 1 May 2026. Article 20 prohibits research-related charges to participants under that framework. Articles 29–34 distinguish approval of clinical translation from research and set conditions for clinical application. Drug and device regulation remains a separate route.
Request the actual decision or product information, authorised indication, responsible institution and current scope. A local hospital announcement cannot be generalised into nationwide product approval.
Status and source check: · RMC editorial review of the linked sources. No clinician review or individual eligibility decision is claimed.
A verified example of an indication-specific approval
One specific Chinese approval is the conditional approval of 艾米迈托赛注射液, a human umbilical-cord MSC product, for steroid-treatment-failed acute graft-versus-host disease mainly involving the digestive tract in patients aged 14 and above. This indication does not establish approval for knee arthritis, diabetes, lung disease, anti-aging or hair restoration.
This is a dated approval example, not a complete list of all authorised cell therapies and not an offer through RMC. The treating institution must provide current product information and assess the patient.
Status and source check: · RMC editorial review of the linked sources. No clinician review or individual eligibility decision is claimed.
Established care and evidence limits
These official patient resources support discussion of established care. They do not establish Chinese approval of a proposed cell intervention. Continue condition-specific specialist care while evaluating any research opportunity.
- NIH / NHLBI: COPD treatment
- NIH / NIAMS: osteoarthritis diagnosis and treatment
- NIH / NIDDK: managing diabetes
- NIH / NICHD: treatment of primary ovarian insufficiency
- US National Cancer Institute: T-cell transfer therapy
Status and source check: · RMC editorial review of the linked sources. No clinician review or individual eligibility decision is claimed.
Unproven stem-cell and exosome claims
RMC does not promise anti-aging, age reversal, a cure, joint regeneration or hair restoration from stem cells or exosomes. Evidence and authorisation must be specific to the proposed product and use.
The FDA consumer alert is US safety guidance dated 22 July 2020. It warns about misleading regenerative-product claims; it is not used here as a current complete list of US approvals or as proof of Chinese regulatory status.
Status and source check: · RMC editorial review of the linked sources. No clinician review or individual eligibility decision is claimed.
Trace each claim to its source
Hospitals and specialist expertise
The directory retains institution-specific official links and their original review dates. Inclusion does not indicate an RMC partnership.
Hospital profiles and original sources →Research and cancer enquiries
What still needs direct confirmation
Current approval scope, foreign-patient intake, individual eligibility, appointments, costs, follow-up and any relationship with a named hospital require written verification. RMC has not confirmed these merely by linking a public source.
Ask about a treatment offer